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Introduction
The mammalian immune system is evolved to protect the host from a diverse range of harmful agents, including tumors. However, malignant tumors present a special challenge to the immune system. Although their abnormalities and expression of neo-antigens should target them for immune destruction, anti-tumor responses are impeded by natural regulatory mechanisms for self-tolerance. Regulatory T cells expressing Foxp3 are a specialized population of T lymphocytes produced by the immune system to control self-tolerance and normal immune homeostasis. Malignant tumors have apparently explored this potent regulatory system to evade immune attack. Extensive studies in cancer patients and experimental animals have shown that tumors are able to recruit and expand naturally occurring Foxp3 + Tregs and also to induce the formation of new cohorts of tumor-specific Tregs to suppress the priming and effector function of tumor killing effector cells. Thus, immune surveillance is largely ineffective and established tumors can aggressively inhibit vaccination or other treatments induced anti-tumor immune responses. Emerging evidence indicates that the mobilization and domination of Tregs in tumorbearing hosts is a sequential and multi-step process involving extensive interaction with different types of APCs, in particular dendritic cells (DC), in tumor tissues and regional lymph nodes. Furthermore, activated Tregs can induce tolerogenic function of APCs. Thus, Treg and APCs in tumor microenvironments form a self-amplifying circuitry to perpetuate dominant immune suppression first at the local site and then systemically over time. Clearly, better understanding of these dynamic processes is of critical importance for the design of effective immunotherapeutic strategies for successful cancer treatment.
Lineage and development of Foxp3

+ regulatory T cells
Intrathymic generation of naturally occurring Foxp3
+ Tregs It becomes clear that Tregs with the hallmark expression of Foxp3 and CD25 are first generated in fetal or neonatal thymus of humans and rodents during early ontogeny (1) (2) (3) . Because thymic generation of CD25 + Foxp3 + Tregs is developmentally programmed without exposure to foreign antigens, they are referred to as naturally occurring Tregs or nTregs (1, 2) . By tracking CD25 and Foxp3 expression, recent studies have revealed that nTregs are primarily formed from CD4 single positive thymocytes (CD4 + SP) during their maturation in the medulla region of the thymus. Intrathymic development of nTregs is dependent on strong T cell antigen receptor (TCR) triggering in the course of positive and negative selection (2) . Thus, nTregs are skewed to react to self-antigens (4, 5) . However, the TCR repertoire of nTregs appears to be equally diverse as other CD4 + T cells (5, 6) . As such, nTregs should have the capacity to respond to a broad range of different antigens (7) . In addition to TCR stimulation, common -chain cytokine signaling has been found to be essential for nTreg development, which includes IL-2, IL-7, IL-15 and perhaps TSLP (8) (9) (10) . Among these membranes, IL-2 appears to be the most important one for driving nTreg development under normal circumstance, while the others can compensate for the loss of function in the absence of IL-2. It has recently been reported that induction of nTregs is likely to involve two discrete steps. First is upregulation of surface expression of CD25 on CD4 + SP receiving strong TCR/CD28 stimulation. Second, CD25 mediates augmented IL-2 signaling inside these cells leading to the activation of Foxp3 gene expression and thereby commitment of the cells to the Treg lineage fate (11, 12) . Whether TGF signaling is involved in Treg development in the thymus remains unsettled. Early studies have shown there is no deficit of intrathymic Foxp3
+ Treg numbers and function in TGF and TGF receptor knockout mice (13, 14) . However, the conclusion that TGF pathway is not involved in thymic development of Tregs has been challenged. A recent work provides new evidence suggesting that the apparent lack of requirement of TGF signaling is due to a possible compensatory role of IL-2 pathway (15) . Indeed, mice with double knockout of IL-2 and TGF receptors exhibit much severe defect in nTreg development (15) . Another critical issue is which types of APCs are required for the selection of nTregs in the thymus. The initial work with human fetal thymus has revealed that DCs activated by TSLP, which is constitutively produced by Hassall's corpuscles in human thymus, are able to drive CD25 +
Foxp3
+ Treg development in thymus medulla (16) . Subsequent reports from animal experiments indicate that medullary thymic epithelial cells (mTECs) expressing autoimmune regulator AIRE are also capable of directing thymic Treg development (17, 18) . Indeed, more recent studies have provided compelling evidence that in fact, mTEC and DC represent two independent pathways and both are involved in Treg selection in thymus (19) . It remains to be investigated whether nTregs selected from these two different pathways have distinct functions and/or antigenic specificities.
Formation of adaptive Foxp3
+ Tregs in the periphery In addition to intrathymic formation of nTregs, CD25 +
Foxp3
+ Tregs can be generated in the periphery when naïve CD4 + precursor cells encounter with antigens (20, 21) . This mechanism of Treg conversion has been unequivocally demonstrated by directly tracking the induction of Foxp3 expression instead of CD25, as some activated effector T cells (Teff) also express CD25 and on the other hand not all Foxp3 + Tregs are CD25 + (22, 23 (46) . Indeed, by intracellular staining tumor-associated Foxp3 + Tregs are found to have increased levels of IL-10 (Qin, unpublished data). However, unlike TGF, IL-10 does not appear to inhibit T cell activation directly. Instead, T cell suppression by IL-10 might be primarily due to its inhibitory function on myeloid APCs (24, 45) . The high expression of PD-1 and PDL-1 on intratumoral Tregs is intriguing. PD-1 and PD-1 ligands are well-known negative costimulation molecules involved in T cell tolerance and clonal anergy/ exhaustion (47) . The role of PD-1 signaling in Treg function is currently undefined. It is possible that PD-1/PDL-1 might interact in cis-configuration to enforce the anergic state of Tregs. Alternatively, they might be involved in T cell and APC inhibition by forward and reverse signaling. Like PD-1, CLTA-4 is another key negative costimulatory molecule essential for T cell tolerance (24, 45) . The tolerance promoting function of CTLA-4 is complex, both Treg-dependent and independent mechanisms have been proposed from previous work (48) . Nevertheless, a most recent study using Treg-specific conditional knockout has provided a definitive evidence for the direct role of CTLA-4 in mediating Treg immune suppression (49) . Thus, elevated expression of CTLA-4 also contributes to the strong immune suppressive activity of tumor-activated Tregs. How CTLA-4 mediates Treg immune suppression remains incompletely understood, but there is convincing evidence pointing to the involvement of dendritic cell tolerization due to interference on CD80/CD86 expression and their costimulatory function (50) (also see discussion below).
Origin of tumor-associated Foxp3
+ Tregs The current knowledge regarding the origin of Tregs accumulated inside tumor lesions largely comes from rodent tumor model studies, which are facilitated by the use of adoptive cell transfer and antigen-specific TCR-transgenic mice. By tracking CD25 and Foxp3 expression, it has been shown that both pre-existing nTregs and aTregs induced from non-Treg precursor cells contribute to the total pool of tumor-infiltrating CD25 + Foxp3 + Tregs (41, 42, 51). Tumor induced aTregs primarily reside in tumor tissues and to a less extent in local draining lymph node as well as blood circulation. Induction is found to be independent of thymic function and can occur in the absence of cell division and proliferation. Interestingly, one study has also shown that depletion of pre-existing nTregs leads to more rapid and extensive conversion of precursor cells to aTregs, which can largely compensate for the loss of nTregs (41). The question of antigen specific for tumor induced aTregs has been examined using TCR-transgenic T cells and tumor expressing a neo-tumor antigen that can be recognized by the transgenic T cells (42, 51). With these model systems, studies show that aTreg induction is triggered by tumor antigen. Similarly, the activation and expansion of nTregs at the tumor site is also antigen dependent. Moreover, both aTregs and nTregs contribute to the tumor specific tolerance. A surprising finding from one of the studies is that immunization intended to boost anti-tumor responses turns out to favor the expansion and mobilization of Tregs rather than tumor killing effector T cells (42). Thus, in the presence of established tumors, tumor vaccine may lead to exacerbated immune suppression due to preferential induction and expansion of tumor specific Tregs. Although information is limited from human studies, several lines of indirect evidence suggest that conversion may take place in cancer patients. First, tumor antigen specific Foxp3 + Tregs have been isolated from tumor tissues as well as peripheral blood from patients with melanoma and cervical cancer (52) (53) (54) . Second, APCs extracted from human leukemia and other cancers can induce Treg conversion from naïve CD4 T cells in vitro (55, 56) . However, distinguishing aTreg from nTregs remains a major challenge. Further studies are warranted to identify phenotypic and functional markers, and perhaps markers of epigenetic modification of the foxp3 gene (57) , that allow unequivocal discrimination of these two regulatory cell populations.
Dynamic processes of Treg recruitment, activation and induction during tumor pathogenesis
Early recruitment of pre-existing nTregs to nascent tumor lesions Carcinogenesis and the development of malignant of tumor involve several distinct stages: the initial hyperplasia, neoplastic growth, angiogenic switch, local invasion and final distant metastasis. Studies with spontaneous and carcinogen induced tumors in mice have revealed the dynamic nature of Treg response to tumor onset and disease progression. In a model of Kras mutation induced spontaneous pancreatic carcinoma, it has been shown that CD25 + Foxp3 + Tregs begin to infiltrate into the incipient tumor lesion at very early stage (58) . Expansion and accumulation of Tregs around the ductal tumor lesion continues through the preinvasive adenoma to invasive adnenocarcinoma phases. Accumulation of Tregs is accompanied with infiltration of other myeloid-derived immune suppressive cells (MDSCs) but has an inverse correlation with effector T cells (58) . Similar observation has made with spontaneous lung adenocarcinoma harboring a Kras mutation (Qin, unpublished data). Treg homing starts at hyperplasia stage and Treg frequency progressive increases during the course of tumor lesion progression to invade adjacent alveolar space. Likewise, studies with 3'-methylcholanthrene induced fibrosarcomas demonstrate that CD25 + Foxp3 + Tregs are recruited to the inflicted site even before tumor transformation takes place and cumulate subsequently along with tumor growth (59, 60) . More importantly, results from these studies also show that partial depletion of Tregs by CD25 antibody treatment reduces the tumor incidence. Conversely, increase of Treg presence leads to accelerated growth of the tumor mass. How does tumor inception and growth induce Treg migration and homing? The idea that tumor development is linked with certain chronic inflammation has been resurged recently by the virtue of better molecular understanding of inflammatory mediators produced inside tumor microenvironments (61) . Two general mechanisms have been proposed to account for tumor-associated inflammation. One is that carcinogen exposure or oncogene activation can trigger intracellular signaling pathways leading to the production of a diverse array proinflammatory chemokines and cytokines in tumor precursor cells. Indeed, in the case of lung cancers, it has been reported that Kras activation in lung bronchoalveolar epithelial cells turns on the expression of KC and MIP2, which are ligands for chemokine receptor CXCR2 (62) . The production of KC and MIP2 is functionally responsible for active recruitment of inflammatory neutrophilic cells to the incipient tumor lesion (62) . Similarly, oncogenic mutation of EGFR in human lung epithelial cells induces high amounts of CCL2, CCL5, IL-1 and IL-1 which can potently recruit and activates monocytes and macrophages (unpublished data). The second mechanism is that tumor cell growth can cause destruction of surrounding extracellular matrix and the death of neighboring cells as well as tumor cell themselves. All these tissue insults will elicit inflammatory response and recruitment of myeloid inflammatory cells (61, 63) . Although the latter mechanism is more likely to operate at more advanced stages with invasive tumors, nonetheless, all these findings together suggest that there is ongoing inflammation inside tumor bed starts at the earliest stage of tumor inception. Chemokine and chemokine receptor usage by Tregs for tumor tissue homing begins to emerge. Studies with human ovarian cancers have shown that Tregs home to tumor mass and ascites via chemokine CCR4 in response to CCL22 secretion from tumor cells and tumor infiltrating macrophages (64) . However, it is unlikely that CCR4 is the only or even major chemokine receptor guiding Treg trafficking in different types of tumors. Studies with humans and mice have revealed that Tregs in peripheral compartments constitutively express a pleiotropic array of chemokine receptors (65, 66) . Expression of some of these receptors is originally thought to be characteristic for memory effector T cells. For example, Tregs express high levels of CXCR3, CCR4 and CCR6, which are shared with memory Th1, Th2 and Th17 cells, respectively (24, 65, 66) . On other hand, unlike naïve CD4 + T cells, Tregs exhibit low expression of CCR7, which functions for lymph node homing and retention. Interestingly, chemokine receptor expression patterns appear to be highly heterogeneous among the peripheral Foxp3 Tregs. For example, some subpopulations express high levels of CCR4 but not CCR6 or CCR9, while another population exhibits CCR9 but no CCR4 and CCR6, yet, the other predominantly CCR6 (65, 66) . The reason for such heterogeneity is unclear but might be related to tissuespecific imprinting through Treg-DC interaction in different tissue microenvironments (24, 30) . Irrespective of the heterogeneity among different subsets, as a whole population, peripheral Tregs must have the ability, like memory cells, to rapidly respond to tissue inflammation without priming. Indeed, in studies with MCA205 fibrosarcoma model, it has been found that donor Foxp3 + Tregs rapidly home to the newly formed tumor lesion directly from the blood circulation within 12-18 h, and is 2-3 times more efficient than homing to the draining lymph nodes (Qin, unpulished data). Intriguingly, Treg trafficking to tumor lesions appears to be orchestrated by myeloid cell infiltration. ovarian cancer patients (64) . Taken together, a working model can be put forward, that is: tumor inception and growth elicits the initial inflammatory signals that attract myeloid cells, and the arrival of myeloid cells will lead to the production of second wave of proinflammatory chemokines which in turn induce the trafficking of circulating Tregs to the tumor site. + Tregs in normal physiological condition, TGF and IL-2 are found to be essential in addition to MHC II and CD80/CD86. It has not been directly tested whether TGF and IL-2 are necessary for nTreg proliferation in tumor microenvironment, although there is a study showing that TGF produced by tumor conditioned DCs is required for stimulating the growth of nTregs in culture (68) . Besides CD80 and CD86, the other potential candidate of costimulatory molecule for mediating Treg activation is GITR. GITR signaling has been shown to induce strong proliferation of Foxp3 + nTregs in vitro in conjunction with TCR and IL-2 stimulation (69). As described above, the cell surface expression of GITR is markedly elevated on intratumoral Tregs. However, it has not been determined whether GITR ligand is substantially produced by any of the tumor-associated APCs. Thus, this possibility remains to be investigated. Toll-like receptor (TLR) pathway is another intriguing mechanism that can potentially modulate Treg activation, suppressor function and proliferation (70 
Local proliferative expansion of nTregs at the tumor site
As discussed above, Foxp3 + Tregs in the established tumor nodules appear to be highly activated and have undergone extensive cellular proliferation. The issue has been raised as to whether these cells are stimulated in situ inside tumor tissues or they are primed in the draining lymph nodes prior to trafficking to the tumor tissue. Currently available data are most consistent with the first scenario. Again, studies with adoptive transfer of nTregs show that expansion of tumor homing Tregs is dependent
Induction of tumor-specific aTregs in the microenvironment of established tumors
Due to the lack of reliable markers to distinguish aTregs from nTregs, direct assessment of the relative contribution of aTregs to the total pool of intratumoral Tregs is difficult. However, as discussed in the previous section, there is ample evidence suggesting that tumor can induce de novo generation of aTregs specific to tumor antigens. There have been intense efforts on identifying tumor-derived factors that promote Treg conversion in tumor microenvironments. The major effect of TGF has been reported from both murine and human studies. For example, many cancer cells produce high amounts TGF, which can drive naïve CD4 + T cells to undergo Treg conversion cell culture systems (56, 73, 74) . In addition, some subsets of DCs isolated from tumor bearing mice are found to have abundant surface-bound TGF and Treg conversion can be induced by these DCs in the TGF dependent manner (68) . As discussed in the previous section, TGF signaling is essential for homeostatic Treg conversion under normal physiological condition. Thus, this mechanism is not unique to tumor, but is apparently co-opted by tumors to function in an uncontrolled manner. In conjunction with TGF, several metabolic pathways that are heightened in tumor microenvironments have been found to stimulate Treg conversion. These include pathways controlled by indoleamine 2, 3 dioxygenase (IDO), arginase and cyclooxygenase 2 (COX-2) (61, (75) (76) (77) (78) . In particular, IDO function has been well documented in several different types of tumors in humans and experimental animals. How IDO activity promotes Treg induction is yet incompletely understood, but it has been shown to involve two parallel pathways. One is local deprivation of amino acid tryptophan, and the other is the production of T cell inhibitory catabolites, kynurenines (75, 76) . A critical question remains to be answered is whether these two pathways can operate on their own to induce Foxp3 gene expression and Treg differentiation, or they act in coordination with TGF signaling. Nevertheless, IDO mediated induction of Foxp3 + Tregs has profound implication in tumor tolerance. In addition to tumor cells, several subpopulations of tolerogenic APCs have been found to express IDO either constitutively or in an inducible manner. For example, CD19 + pDCs in tumor draining lymph nodes have been shown to have high constitutive levels of IDO, and this type of dendritic cells can potently induce T cell apoptosis, anergy and Treg conversion (79) . More interestingly, upon interaction with activated Tregs some DCs can upregulate IDO expression. It has been proposed that IDO induction in DCs is mediated by reverse signaling of CD80/CD86 through the engagement with CTLA-4 expressed on the cell surface of Tregs (76) . Since intratumoral Tregs have significantly higher levels of CTLA-4 expression, it is conceivable that this pathway operates very efficiently inside tumor tissues. A more recent study has further shown that IDO activity may exert a feed-forward effect on the tolerogenic function of DCs, which is due to reinforcement of TGF production and signaling (80) . Consistent with the important role of IDO in immune suppression, blocking IDO enzymatic activity by MT-1, a small molecule inhibitor, has been shown to be effective in reversing tumor tolerance (75, 76) . However, it should be pointed out that IDO is not the only mechanism at work in Treg-APC crosstalk. Several other pathways have also been implicated in this process, which include PD-1, ICOS, B7-H3 and B7-H4 (46, 79, (81) (82) (83) . Therefore, the Treg-APC suppressive network is likely to be built through multiple signaling modules each of which may affect the suppressive and tolerogenic functions either qualitatively or quantitatively. The significance of such networking is not only to maintain local tolerance, but also to gradually amplify and broaden immune suppression systemically by inducing more tolerogenic DCs and new cohorts of tumor-specific Tregs. In support of this view, studies with metastatic model of Lewis Lung Carcinoma show that although initial recruitment and expansion is restricted to the primary tumor site, over time it spreads over first to local draining lymph node, then distal lymph nodes, the spleen and blood circulation. Progressively tumor-induced aTregs increase in their prevalence in the total pool of Tregs in various compartments (Qin, unpublished data). It remains to be tested whether generalized Treg expansion and mobilization is essential for the tumor cells to metastasize distant target organs. However, there are substantial numbers of clinical cases suggesting that high level and broadened accumulation of Foxp3 + Tregs predicts metastatic invasion and disease recurrence (84).
Alteration of Treg homeostasis by cancer treatment
It has now been widely acknowledged that Treg is one critical parameter to be considered for designing therapeutic treatments for cancers, in particular immunotherapies. Ironically, many current existing treatment modalities may affect Treg dynamics and function in a counter-productive way. For example, IL-2 has been used to treat several different types of chemo/radia refractory cancers base on the rationale of the cytokine's stimulatory function to CD4 + and CD8 + effector T cells and NK cells. However, recent clinical studies have shown that IL-2 administration may lead to marked expansion of CD25 + Foxp3 + Tregs and increase of immune suppression mediated by the expanded Treg populations in the patients (85-88). Furthermore, one study also reveals that IL-2 can alter the trafficking pattern of Tregs due to upregulation of chemokine receptor CXCR4, which promotes Treg homing to the tumor mass of ovarian cancers (87). Importantly, although not all patients respond to IL-2 treatment, the increase of Treg accumulation in the tumor mass induced by IL-2 appears to inversely correlate with beneficial outcome of the treatment. In addition to IL-2, other common gamma chain cytokines, including IL-7 and IL-15, have entered into clinical trials recently for cancer therapy, because they can strongly boost effector and memory function of tumor killing NK cells, CD4 + and CD8 + T cells. However, there are compelling experimental data suggesting these members may similarly drive Treg expansion and mobilization as IL-2 (89-91). Thus, dynamic responses of Foxp3 + Treg populations to these treatments need to be carefully monitored in evaluating potential clinical benefit and therapeutic prediction.
Vaccine holds great promise for cancer treatment. It is well known that vaccination with tumor antigens can elicit potent and specific tumor killing effector T cells, including both CD4 + helper cells and CD8 + cytotoxic cells (CTLs). How vaccination may affect Tregs remains inadequately studied. However, recent work in this area has raised a major concern on potentially deleterious effect of cancer vaccines in hosts bearing advanced tumors due to their adverse impact on Tregs (42, 92, 93). For example, an animal study shows that immunizing tumor-bearing mice with vaccinia vaccines carrying a model tumor antigen not only elicits anti-tumor effector T cells, but also tumor antigen-specific Tregs at the same time (42). In particular, for hosts bearing large advanced tumors, Treg induction and expansion become dominant and result in poor effector cell activation and tumor rejection function. Thus, in this scenario, therapeutic vaccination actually worsens host tolerance to tumor antigens. Although the factors and underlying mechanisms for such phenomenon remain elusive, it is consistent with the view discussed in the previous sections that the establishment of immune suppressive network composed of Foxp3 + Tregs in the tumor microenvironment particularly condones further induction and expansion of new populations of Tregs. Clinical investigations with anti human papillomavirus (HPV) E6/E7 vaccines in cervical cancer patients provide further support to general implication of concomitant induction of tumor antigen-specific Tregs (92). In the reported clinical trials, HPV peptide vaccines have been found to elicit the peptide reactive Tregs with CD4 + CD25 + Foxp3 + phenotype, which can potently suppress effector cells of the same antigenic specificity (92). All these findings suggest that vaccination strategies seeking not only to increase the frequency of tumor-specific effector T cells, but also to prevent Treg induction is essential for a successful treatment.
Chemotherapy remains the mainstay of treatment for malignant cancers. Many of chemo agents not only function in killing tumor cells but also have profound influence to the immune system, especially the adaptive immune system. Interest in the immunological aspects of conventional chemotherapy has resurged recently as now it becomes possible to segregate positive and negative effects with improved understanding on the mechanisms for immune regulation (94). For example, the DNA alkylating molecule, cyclophosphamide (CPM) has been known for long time to have immunomodulatory effects on T cells and promote anti-tumor immunity (95). It has now been confirmed that + Tregs after CPM treatment is currently unknown, but it appears to involve both mechanisms of proliferative expansion of residual nTregs and induction of new populations of aTregs (Qin, unpublished data). Interestingly, Treg rebound is more rapid and robust in tumor tissues, thus again illustrating the conducive nature of tumor micro-environment for Treg dominance. In addition to CPM, another class of chemo agent represented by fludarabine has been found to produce similar results of selective Treg reduction in cancer patients (100). Like CPM, fludarabine induced Treg depletion is transient, Treg populations recover rapidly after cessation of the drug (100). Taken together, Treg homeostasis appears to be very robust, and as a whole, the Treg population can quickly restore to their preset point after temporarily off balance. This feature is particularly relevant to tumor-bearing hosts as the overall atmosphere is in bias towards Treg expansion, so that treatments may ultimately cause more generalized immune suppression due to widespread accumulation of Tregs throughout the body.
Targeted depletion of Tregs has been widely viewed as a promising strategy for breaking immune suppression and thereby boosting natural and therapeutically induced antitumor immunity. Because nTregs and aTregs constitutively express high levels of CD25, the IL-2 receptor alpha chain, which confers high affinity binding to the cytokine, currently available manipulations are directed towards this distinct property. In mice, CD25 + Tregs can be successfully depleted by a specific anti-murine CD25 monoclonal antibody, PC61 (101). Earlier studies demonstrate that systemic depletion of pre-existing Tregs promotes spontaneous immune responses to tumors and allows the host to successfully reject several different types of transplantable tumors (102). Subsequently, it has been shown that Treg ablation by anti-CD25 antibody treatment prior to tumor antigen vaccination can significantly improve vaccine efficacy at both CTL priming and effector function levels (103). The positive outcomes from animal model studies have led to recent clinical trails for treating cancer patients by CD25 + Treg depletion (104) . In human studies, the therapeutic immunotoxin denileukin difitox (Ontak), a recombinant fusion protein of IL-2 and diphtheria toxin, has been used to selectively kill T cells expressing high levels of CD25. Several published reports show that administration of Ontak in patients results in reduction of CD25 + Foxp3 + Tregs in peripheral blood, which correlates with heightened DTH response and increase of antigenspecific CTLs in response to tumor antigen immunization (105) (106) (107) . However, the effect of Ontak on Treg depletion may not be consistent, as there is no significant reduction in certain caner patients (108) . Furthermore, like chemotherapeuitc agents discussed in the previous section, depletion incurred by Ontak appears to be transient, and Treg populations are restored rapidly after the treatment cessation (105) (106) (107) 109) . These events are likely to cause persistent and even broadened immune suppression and tolerance to tumor antigens in the presence of high tumor burden (40, 109). Therefore, as discussed in the previous sections, the recurrent theme is that Treg has inherently high capacity for self-replenishment and this function can be fueled up further in the hosts with progressively growing tumors. At present, the factors and signaling pathways driving Treg homeostatic proliferation and replenishment remain unclear, but it is certainly an area of pressing importance for further investigation.
Concluding remarks
Foxp3
+ Treg populations are highly dynamic in tumor bearing hosts with regard to their origins, phenotypes and functional states. Malignant tumors can actively recruit, expand and induce de novo generation of Foxp3 + Tregs specific to tumor antigens to suppress multiple beneficial immune responses during disease progression. Tumorinduced Tregs not only inhibit the priming and effector function of anti-tumor effector cells, but also form a broad and self-amplifying immune suppressive network through extensive interaction with various APCs. Thus, targeting Treg recruitment, induction, expansion and their nexus with tolerogenic APCs would promote both host immune surveillance and vaccine induced anti-tumor immunity. However, since Tregs are normally required for maintaining self-tolerance, cautions need to be taken when therapeutic manipulation of Tregs is applied to treat cancer patients.
Global and non-specific depletion of Tregs is of limited utility. First, prolonged total Treg depletion may breach self-tolerance control leading to autoimmune disease. Second, Tregs have a robust homeostatic capacity, especially in tumor-bearing hosts, and the populations can rapidly rebound and may over-compensate beyond the pretreatment level after a temporary decline. Therefore, strategies need to be developed to selective curtail tumor specific processes locoregionally at the tumor site. In addition to inhibiting the recruitment, activation and proliferative expansion of nTregs, it is particularly appealing to develop strategies to block de novo generation of tumor-specific Tregs. The purpose is multifold: 1) it will eliminate the most potent suppressors that inhibit tumor killing effector cells; 2) it can redirect precursor T cells that recognize tumor antigens to differentiate into effector cells that can themselves attack tumor cells. Furthermore, this approach is less likely to affect the normal pool of nTregs, thus carries minimal risk of triggering autoimmunity. Recent advance in understanding Treg cell fate determination and cross-regulation of Treg and effector CD4 T cell lineage programs has provided new perspectives on how to achieve such a goal. Not only may this be done by neutralizing positive factors that promote aTreg differentiation but also by administrating negative factors that can effectively antagonize Foxp3 + lineage fate choice. There is no doubt that safer and more efficacious immunotherapies will come out from the ever intensified research efforts to better understand the fundamental cellular and molecular mechanisms governing the dynamic processes of Treg response to tumor development in the host. The knowledge gained from these studies may also shed interesting light on the general aspects of Treg biology and provide relevant information on treatment strategies for other diseases where the balance of Tregs and effector T cells is centrally important. 
